RNA

Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

MILWAUKEE, July 11, 2007 /PRNewswire/ -- A new study suggestsstrong variation in the occurrence of anaphylaxis between thenorthern and southern U.S. Anaphylaxis is a severe allergicreaction that can be fatal without treatment with epinephrine. Thestriking north-south differences in EpiPen prescribing, a marker ofanaphylaxis risk, currently are without explanation. Theinvestigators hypoth...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nasdaq GM:NTEC) today announced that two poster presentationswere presented with its collaborative partner, Novo Nordisk A/S,relating to GlycoPEGylated recombinant Factor VIIa at the XXIstCongress of the International Society on Thrombosis and Haemostasisin Geneva, Switzerland. The data presented demonstrates thatGlycoPE...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

WINNIPEG, Manitoba - (July 11, 2007) Medicure Inc. (TSX:MPH;Amex:MCU), a cardiovascular focused, biopharmaceutical company,today announced that the two-year, follow-up results from theSTRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-ElutingStent Versus Abciximab and Bare Metal Stent In Acute MyocardialInfarct...

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on Thrombosis andHaemostasis (ISTH)...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced positive Phase II data on its leadcompound, PRT054021, an oral Factor Xa inhibitor, today at the XXICongress of the International Society on Thrombosis and Haemostasis(ISTH) in Geneva, Switzerland. The EXPERT trial showed thatPRT054021 was safe, effective, and well tolerated for theprevention of venous th...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression

Findings Published in Molecular Cell Show Potential of microRNAs asNovel Cancer Drug Targets REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 05, 2007/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNAcompany, announced today research published in the journalMolecular Cell by scientists from the Weizmann Institute of Scienceand Rosetta Genomics . The findings suggest...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...

Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis

SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo,Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM(Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase2 trial looking at recombinant nematode anticoagulant protein c2(rNAPc2) in patients with acute coronary syndromes (ACS),preclinical data evaluating rNAPc2 in mouse models of colorectalcancer, and precli...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced today that it will present clinicaland preclinical data on its oral Factor Xa inhibitor and on itsintravenous and oral ADP receptor antagonist at the XXI Congress ofthe International Society of Thrombosis and Haemostasis (ISTH) inGeneva, Switzerland on July 6 through July 12, 2007. The EXPERT...

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality ofCompany's Once-Daily Tramadol to be Published in BiopharmaceuticsJournal - LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc.today announced that it will present a poster discussing the dosetitration of its once-daily formulation of tramadol at the 3rdInternational Forum on Pain Medicine to be held June 28 to J...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford

STANFORD, Calif.--(BUSINESS WIRE)--Jun 29, 2007 - The drug mostcommonly used to arrest preterm labor, magnesium sulfate, is morelikely than another common treatment to cause mild to serious sideeffects in pregnant women, according to a study from researchers atLucile Packard Children's Hospital and Stanford University Schoolof Medicine. Their findings suggest that, since the effectivenessof...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced today the presentation of twoposters at the XIth Annual International Myeloma Workshop beingheld in Kos, Greece from June 25-28th, 2007. The meeting highlightsimportant advances made in the biology and treatment of multiplemyeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) geneexpression profil...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CytogenCorporation (NASDAQ: CYTO) reported updated data from a Phase 1dose escalation study evaluating QUADRAMET(R) (samarium Sm-153lexidronam injection) in combination with bortezomib (Velcade(R),Millennium Pharmaceuticals, Inc.) in patients with relapsedmultiple myeloma. Data from 33 patients were presented today in aposter titled, "Phase 1...

New Proof of Genistein's Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals ofInternal Medicine has published the results of a two-year clinicalstudy on the impact of genistein on bone loss. The paper, "Effectsof the Phytoestrogen Genistein on Bone Metabolism in OsteopenicPostmenopausal Women-A Randomized Trial," appears in the currentissue (June 19, 2007) and details the safety and efficacy ofgenistein for...

Genetics Journal Thimerosal/Autism Study the 'Best Science Drug Company Money Can Buy'

Critique of Industry-Funded Immune Globulin Study Uncovers SampleManipulation, Design Flaws NIXA, Mo., June 26, 2007 /PRNewswire-USNewswire/ -- An analysisreleased today critically examined a recent industry-sponsoredstudy ruling out a link between autism and Rh immune globulin(RhIg) injections, some of which contained the mercury-basedpreservative thimerosal. Besides extensive design fla...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of Vekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference

BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.(OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that newdata presented at an international influenza research conferencedemonstrates that HepaLife's patented PBS-1 cell line outperformscurrent cell technologies at replicating human influenza virusinside its cells. The most important step towards the production ofa cel...

BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

Independent Study Indicates 20-50% Improvement in Post-PreservationFunctional Recovery of Peripheral Blood Stem Cells for CancerTherapy BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- BioLifeSolutions Inc. , a leading developer and marketer of proprietaryhypothermic storage and cryopreservation media products for cells,tissues, and organs, today presented data from an independent...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) announced today that an interimanalysis of a pregnancy study comparing the efficacy of CRINONE(R)8% (progesterone gel) to compounded intramuscular progesterone(IMP) injections is now available online and will be published inFertility and Sterility, the journal of the American Society forReproductive...

MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia

"Electroloading of mature dendritic cells with tumor lysatetriggers robust antigen-specific CTL response" GAITHERSBURG, Md., and YOKOHAMA, Japan, June 22, 2007/PRNewswire/ -- MaxCyte, Inc. and Medinet Co., Ltd. announce ajoint poster presentation at the 13th Annual Meeting of theInternational Society for Cellular Therapy. The meeting is beingheld June 24-27, 2007 in Sydney, Australia....

Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007- The Institute for OneWorld Health, a US-based non-profitpharmaceutical company, today announced that Phase 3 researchrelated to its first approved drug product, Paromomycin IMInjection (Paromomycin), was published in the current issue of TheNew England Journal of Medicine (NEJM). This clinical trial showsthat the medicine...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of the Phase 2proof-of-concept data from the Anthem (Anticoagulation with rNAPc2To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June26th issue of the Journal of of Cardiology (JACC), demonstratingthat higher-dose (greater than or equal to 7.5 mcg/kg) recombinantnematode a...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

Trophos Describes Identification, Characterization and BroadNeuroprotective Properties of TRO19622 in Journal of Pharmacologyand Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a NovelDrug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceuticalcompany specializing in the discovery an...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

-- More than 70 abstracts highlight VELCADE efficacy in broad rangeof patients and across continuum of care -- CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today announced that data forVELCADE, the market leading therapy with unsurpassed single-agentefficacy for patients with previously treated multiple myeloma(MM), will be featured at the upco...

Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey

MALVERN, Pa., June 15, 2007 /PRNewswire/ -- SolsticeNeurosciences, Inc. today reported important results from amulticenter, forced dose escalation study of Botulinum Toxin Type BInjectable Solution (Myobloc(R)) recently presented at the 11thInternational Congress of The Movement Disorders Society inIstanbul, Turkey. This was the first multicenter study to confirm patient safetyand...

Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop

PRINCETON, N.J., June 14, 2007 /PRNewswire-FirstCall/ --Pharmasset, Inc. , a clinical-stage pharmaceutical companycommitted to discovering, developing and commercializing noveldrugs to treat viral infections, announced today that scientificdata presentations about Clevudine and Racivir were made during the16th International HIV Drug Resistance Workshop being held in St.Michael, Barbados...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - CriticalTherapeutics, Inc. (Nasdaq: CRTX) today announced the publicationof data from a pivotal Phase III clinical trial of ZYFLO CR(TM)(zileuton) extended-release tablets in the June 2007 issue of theJournal of Asthma. ZYFLO CR was approved by the U.S. Food and DrugAdministration (FDA) on May 30, 2007. Critical Therapeutics,together with it...

Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc.today is presenting data from an open-label extension of its PhaseIIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD)at the Alzheimer's Association's International Conference onPrevention of Dementia in Washington, D.C. Consistent with thefindings of earlier clinical and preclinical studies, AC-1202 wasshown to...

July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Results from thesuccessful clinical trial of Oscient Pharmaceuticals' (Nasdaq:OSCI) FACTIVE(R) (gemifloxacin mesylate) tablets for the five-daytreatment of community-acquired pneumonia of mild to moderateseverity (CAP) have been published in the July issue of thepeer-reviewed Journal of Antimicrobial Chemotherapy, currentlyavailable in advance...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...

Data Showing that ReGen's Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia

London, UK, June 11, 2007-ReGen is pleased to announce thata review of scientific and clinical information on Colostrinin, itsnutraceutical product which the Company believes has the potentialto support healthy cognitive function, was presented today at the2007 International Congress on Natural Medicine in SurfersParadise, Queensland, Australia by Dr Marian Kruzel, ReGen's ChiefScientifi...

IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders

HAYWARD, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - IMPAX Laboratories,Inc. (OTC:IPXL) today announced that two poster presentations,highlighting the company's compound, IPX054, a combined immediate-and extended-release carbidopa/levodopa (CD/LD) product to bemarketed as VADOVA(TM), were presented at the Movement DisorderSociety's 11th International Congress of Parkinson's Disease andMovement D...

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIRPharmaceuticals (NASDAQ:AVNR) today announced the presentation ofPhase III data, including efficacy, safety and improvements inpatient-centered outcomes in patients with diabetic peripheralneuropathic (DPN) pain treated with the investigational drugZenvia(TM) (dextromethorphan/quinidine (DM/Q)), an NMDA receptorantagonist and sigma-1...